U.S. Food and Drug Administration Grants Arsenal Medical Investigational Device Exemption Approval to Conduct Clinical Study on ResQFoam Safety and Effectiveness

My Subscriptions

Payment Confirmation

Transaction Failed

Your transaction failed, please try again or contact site support.

Arsenal Medical announced today they have received unconditional IDE approval from FDA to conduct a clinical study to examine the safety and effectiveness of ResQFoamTM, a self-expanding material for the treatment of severe internal bleeding in trauma patients. This study will take place in trauma centers throughout the United States and is supported by funding from the US Army Medical Research and Materiel Command (USAMRMC). The study is designed to support ultimate product approval in the United States.

ResQFoam is a biocompatible, self-expanding biomaterial, designed to be administered at the point of injury to stop massive blood loss in patients suffering from life-threatening abdominal trauma. The material fills and conforms to the abdominal cavity to control bleeding before being removed at the time of surgery. ResQFoam may provide a life-saving bridge to surgical care for those who may otherwise die before reaching surgical care, both in civilian and military settings. Abdominal bleeding accounts for the majority of preventable fatalities in injured warfighters.

Dr. David King, the Principal Investigator for the study, and a trauma surgeon at Massachusetts General Hospital, and a Lieutenant Colonel in the US Army highlights, “Many patients and military personnel with massive abdominal bleeding will die before they reach surgical care.   He went on to say, “Quickly stabilizing these patients can substantially increase their chances of survival.” As a trauma surgeon in the army, Dr. King has served multiple tours of duty in Iraq and Afghanistan. He and his research team have collaborated with Arsenal Medical on the development of ResQFoam.”

The company reports the pre-clinical data on the ResQFoam device has been described in more than ten peer-reviewed manuscripts and at several national trauma conferences. After review of this data, the Food and Drug Administration approved an investigational device exemption (IDE) enabling clinical study of ResQFoam in severely injured trauma patients.

The study will be conducted at multiple trauma centers throughout the United States. King concluded, “Even in our most capable hospitals, almost half of the patients with severe abdominal trauma die before reaching the operating room.  By conducting the clinical study in these hospitals, we can obtain robust data on the safety and effectiveness of ResQFoam.”

“A clinical study of ResQFoam has the potential to save lives while obtaining critical data on the safety and effectiveness of the device.” said Dr. Upma Sharma, Program Director for the USAMRMC contract and Vice President of Research and Development at Arsenal Medical. “This clinical study is the next critical step to an FDA approval, which will enable the use of this device to save patients with injuries who might otherwise die prior to reaching surgical care.”



Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.